MARKET

ADMA

ADMA

ADMA Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.090
+0.500
+19.31%
After Hours: 3.090 0 0.00% 18:59 04/03 EDT
OPEN
2.580
PREV CLOSE
2.590
HIGH
3.120
LOW
2.500
VOLUME
4.61M
TURNOVER
--
52 WEEK HIGH
5.48
52 WEEK LOW
1.450
MARKET CAP
266.81M
P/E (TTM)
-3.4117
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADMA stock price target is 11.00 with a high estimate of 15.00 and a low estimate of 6.00.

EPS

ADMA News

More
  • FDA Says Some Limited Data To Suggest Convalescent Plasma & Hyperimmune Globulin May Have Benefit In Coronavirus
  • Reuters · 6h ago
  • FDA Is Facilitating Access To Convalescent Plasma For Treating Coronavirus Using Multiple Pathways, Plans To Provide Convalescent Plasma To Patients In Need Who May Not Have Access To Institutions With Clinical Trials In Place
  • Dow Jones-Dow Jones · 6h ago
  • Edited Transcript of ADMA earnings conference call or presentation 12-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • ADMA Biologics: Not Immune To Coronavirus Sell-Off Despite Their Ability To Help
  • Seeking Alpha - Article · 03/25 15:57

Industry

Biotechnology & Medical Research
-0.74%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About ADMA

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
More

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.